[Sudden cardiac death, ICD and resynchronization therapy]

Area of Science:

• Cardiology
• Electrophysiology
• Medical Device Technology

Background:

• Current guidelines recommend implantable cardioverter-defibrillators (ICDs) for primary prevention of sudden cardiac death (SCD).
• Key trials like MADIT II, Companion, and SCD-HeFT established the efficacy of ICDs in specific patient populations.
• Risk stratification for SCD is crucial in managing patients with cardiovascular disease.

Observation:

• The primary risk factors for life-threatening ventricular arrhythmias include prior myocardial infarction, impaired left ventricular function, and chronic heart failure.
• Case reports illustrate the clinical scenarios necessitating ICD or biventricular defibrillator (BIV-ICD) implantation.
• These cases highlight the practical application of guidelines in patient selection for defibrillator therapy.

Findings:

• Implantation of cardioverter-defibrillators is indicated for primary prevention of sudden cardiac death.
• Reduced left ventricular function and a history of myocardial infarction are significant predictors of ventricular arrhythmias.
• Biventricular defibrillators offer a therapeutic option for specific heart failure patients.

Implications:

• These findings support the integration of ICDs into clinical pathways for patients at high risk of sudden cardiac death.
• Defibrillator therapy can significantly reduce mortality in selected heart failure patients.
• Further research may refine patient selection criteria for optimal defibrillator implantation outcomes.